Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.44 |
| ▸ | PDE4A | P27815 | 6/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.43 |
| ▸ | FPR2 | P25090 | 4/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 2/20 | 0.36 |
| ▸ | DCK | P27707 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876107 | 0.89 | PDE4B (0.41) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL5244187 | 0.88 | PDE4B (0.42) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL5244019 | 0.87 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4867660 | 0.86 | PDE4B (0.42) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4878067 | 0.86 | PDE4A (0.46) | PDE4BPDE4APDE4CPDE4DMIF | |
| SCHEMBL4881015 | 0.85 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DMIF | |
| SCHEMBL5245410 | 0.84 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4877799 | 0.84 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DMIF | |
| SCHEMBL5247867 | 0.84 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DMIF | |
| SCHEMBL5244619 | 0.83 | PDE4B (0.39) | PDE4BPDE4APDE4CPDE4DFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009535-A1 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | claimed |
| EP-1840123-A1 | Isoxazolines and their use as inhibitors of phosphodiesterase type-IV | Ranbaxy Laboratories Limited (IN) | 2007-10-03 | — | — | EP | claimed |
| US-20080009535-A1 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | disclosed |
| EP-1840123-A1 | Isoxazolines and their use as inhibitors of phosphodiesterase type-IV | Ranbaxy Laboratories Limited (IN) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009535-A1 | Inhibitors of phosphodiesterase type-IV | PDE4A, PDE3B, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.